Triple-negative breast cancers (TNBCs) remain one of the most challenging subtypes of breast cancer to be treated clinically. , Currently, no targeted therapies are available leaving chemotherapy the only option. Here, I describe a novel approach to inhibit highly overexpressed transcription factors (TFs) in TNBCs that drive high cell proliferation and poor survival in these tumours, by harnessing interference peptides to specifically block the binding of these TFs to their endogenous cofactors. The body of work outlined in this thesis demonstrates the power of novel targeted approaches to sensitise highly metastatic and resistant tumours to chemotherapy.
|Qualification||Doctor of Philosophy|
|Award date||15 Mar 2019|
|Publication status||Unpublished - 2019|